BR112021004317A2 - processos alternativos para a preparação de tubulisinas e intermediários das mesmas - Google Patents

Info

Publication number

BR112021004317A2

BR112021004317A2 BR112021004317-9A BR112021004317A BR112021004317A2 BR 112021004317 A2 BR112021004317 A2 BR 112021004317A2 BR 112021004317 A BR112021004317 A BR 112021004317A BR 112021004317 A2 BR112021004317 A2 BR 112021004317A2

Authority

BR

Brazil

Prior art keywords

moiety

optionally substituted

formula

linker

compound

Prior art date

2018-09-07

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000543 intermediate Substances 0.000 title claims abstract description 103
• 238000000034 method Methods 0.000 title claims abstract description 82
• 238000002360 preparation method Methods 0.000 title abstract description 18
• 230000008569 process Effects 0.000 title abstract description 8
• 150000001875 compounds Chemical class 0.000 claims abstract description 333
• 239000000203 mixture Substances 0.000 claims description 429
• 230000003287 optical effect Effects 0.000 claims description 279
• 150000003839 salts Chemical group 0.000 claims description 273
• -1 9-fluorenyl Chemical group 0.000 claims description 141
• 229910052717 sulfur Inorganic materials 0.000 claims description 119
• 239000012535 impurity Substances 0.000 claims description 107
• 238000000926 separation method Methods 0.000 claims description 45
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 41
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 38
• 239000002253 acid Substances 0.000 claims description 36
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
• 150000001450 anions Chemical class 0.000 claims description 31
• 238000006243 chemical reaction Methods 0.000 claims description 31
• 239000003638 chemical reducing agent Substances 0.000 claims description 29
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 28
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 26
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 25
• 229910052760 oxygen Inorganic materials 0.000 claims description 25
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
• 239000011541 reaction mixture Substances 0.000 claims description 21
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 20
• 239000003880 polar aprotic solvent Substances 0.000 claims description 19
• 238000005966 aza-Michael addition reaction Methods 0.000 claims description 18
• 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 16
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
• 239000003446 ligand Substances 0.000 claims description 16
• 238000010791 quenching Methods 0.000 claims description 16
• 230000000171 quenching effect Effects 0.000 claims description 16
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
• 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 12
• 239000011230 binding agent Substances 0.000 claims description 12
• 125000006244 carboxylic acid protecting group Chemical group 0.000 claims description 12
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 10
• 230000000717 retained effect Effects 0.000 claims description 10
• KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 8
• 230000005595 deprotonation Effects 0.000 claims description 8
• 238000010537 deprotonation reaction Methods 0.000 claims description 8
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
• 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims description 6
• 238000001816 cooling Methods 0.000 claims description 6
• 238000003756 stirring Methods 0.000 claims description 5
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
• 239000002904 solvent Substances 0.000 claims description 4
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
• 238000002156 mixing Methods 0.000 claims description 3
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
• 239000000741 silica gel Substances 0.000 claims description 2
• 229910002027 silica gel Inorganic materials 0.000 claims description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
• 229940126062 Compound A Drugs 0.000 claims 2
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
• 238000003818 flash chromatography Methods 0.000 claims 1
• BDOLXPFAFMNDOK-UHFFFAOYSA-N oxazaborolidine Chemical compound B1CCON1 BDOLXPFAFMNDOK-UHFFFAOYSA-N 0.000 claims 1
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical group C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims 1
• 229940079593 drug Drugs 0.000 abstract description 205
• 239000003814 drug Substances 0.000 abstract description 205
• 230000027455 binding Effects 0.000 abstract description 90
• 230000001976 improved effect Effects 0.000 abstract description 3
• 235000013350 formula milk Nutrition 0.000 description 396
• 125000005647 linker group Chemical group 0.000 description 230
• 210000004027 cell Anatomy 0.000 description 185
• 239000000562 conjugate Substances 0.000 description 175
• 125000001424 substituent group Chemical group 0.000 description 131
• 125000005842 heteroatom Chemical group 0.000 description 129
• 229910052799 carbon Inorganic materials 0.000 description 120
• 125000004432 carbon atom Chemical group C* 0.000 description 106
• 229910052757 nitrogen Inorganic materials 0.000 description 96
• 235000002639 sodium chloride Nutrition 0.000 description 94
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 92
• 230000007062 hydrolysis Effects 0.000 description 81
• 238000006460 hydrolysis reaction Methods 0.000 description 81
• 230000002159 abnormal effect Effects 0.000 description 75
• 125000003118 aryl group Chemical group 0.000 description 74
• 125000000524 functional group Chemical group 0.000 description 69
• 125000004122 cyclic group Chemical group 0.000 description 68
• 125000000217 alkyl group Chemical group 0.000 description 60
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 59
• 150000001721 carbon Chemical group 0.000 description 58
• 125000000623 heterocyclic group Chemical group 0.000 description 53
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 52
• 239000002585 base Substances 0.000 description 52
• 125000002015 acyclic group Chemical group 0.000 description 51
• AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 50
• 239000003795 chemical substances by application Substances 0.000 description 47
• 125000006850 spacer group Chemical group 0.000 description 47
• 108090000765 processed proteins & peptides Proteins 0.000 description 44
• 102000035195 Peptidases Human genes 0.000 description 43
• 108091005804 Peptidases Proteins 0.000 description 43
• 239000004365 Protease Substances 0.000 description 43
• 239000000427 antigen Substances 0.000 description 42
• 102000036639 antigens Human genes 0.000 description 42
• 108091007433 antigens Proteins 0.000 description 42
• 150000008134 glucuronides Chemical group 0.000 description 42
• 125000003342 alkenyl group Chemical group 0.000 description 41
• 125000001072 heteroaryl group Chemical group 0.000 description 40
• 125000004429 atom Chemical group 0.000 description 39
• 229910052739 hydrogen Inorganic materials 0.000 description 38
• 239000001257 hydrogen Substances 0.000 description 38
• 229920006395 saturated elastomer Polymers 0.000 description 38
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 35
• 230000008685 targeting Effects 0.000 description 35
• 206010028980 Neoplasm Diseases 0.000 description 33
• 229920001223 polyethylene glycol Polymers 0.000 description 33
• 238000006722 reduction reaction Methods 0.000 description 33
• 230000009467 reduction Effects 0.000 description 32
• 239000004606 Fillers/Extenders Substances 0.000 description 31
• 125000004452 carbocyclyl group Chemical group 0.000 description 31
• 125000004433 nitrogen atom Chemical group N* 0.000 description 31
• 150000002148 esters Chemical group 0.000 description 30
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 27
• 239000002202 Polyethylene glycol Substances 0.000 description 25
• 125000000732 arylene group Chemical group 0.000 description 25
• 230000000694 effects Effects 0.000 description 25
• 210000002865 immune cell Anatomy 0.000 description 25
• 125000002947 alkylene group Chemical group 0.000 description 24
• 125000000304 alkynyl group Chemical group 0.000 description 24
• 150000001408 amides Chemical class 0.000 description 24
• 150000001413 amino acids Chemical class 0.000 description 24
• 125000006239 protecting group Chemical group 0.000 description 24
• 238000003776 cleavage reaction Methods 0.000 description 23
• 230000007017 scission Effects 0.000 description 23
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 22
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 22
• 229940024606 amino acid Drugs 0.000 description 22
• 235000001014 amino acid Nutrition 0.000 description 22
• 150000001720 carbohydrates Chemical class 0.000 description 22
• JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 22
• 201000011510 cancer Diseases 0.000 description 21
• 239000007844 bleaching agent Substances 0.000 description 20
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 19
• 239000012634 fragment Substances 0.000 description 19
• 239000002243 precursor Substances 0.000 description 19
• 230000003463 hyperproliferative effect Effects 0.000 description 18
• 125000004434 sulfur atom Chemical group 0.000 description 18
• 125000003710 aryl alkyl group Chemical group 0.000 description 17
• 125000005549 heteroarylene group Chemical group 0.000 description 17
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 17
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 16
• 150000002431 hydrogen Chemical class 0.000 description 15
• 125000000547 substituted alkyl group Chemical group 0.000 description 15
• 150000003573 thiols Chemical group 0.000 description 15
• 125000003277 amino group Chemical group 0.000 description 14
• 230000002255 enzymatic effect Effects 0.000 description 14
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 13
• 125000004450 alkenylene group Chemical group 0.000 description 13
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 13
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
• 238000006467 substitution reaction Methods 0.000 description 13
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 13
• 125000000041 C6-C10 aryl group Chemical group 0.000 description 12
• 230000021615 conjugation Effects 0.000 description 12
• 229940127121 immunoconjugate Drugs 0.000 description 12
• 241000894007 species Species 0.000 description 12
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 11
• 150000001412 amines Chemical class 0.000 description 11
• 238000004061 bleaching Methods 0.000 description 11
• 150000003949 imides Chemical class 0.000 description 11
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 10
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 10
• 238000006845 Michael addition reaction Methods 0.000 description 10
• 125000000753 cycloalkyl group Chemical group 0.000 description 10
• 230000035755 proliferation Effects 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 229960002317 succinimide Drugs 0.000 description 10
• 229910052721 tungsten Inorganic materials 0.000 description 10
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 9
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 9
• 125000004103 aminoalkyl group Chemical group 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 238000004587 chromatography analysis Methods 0.000 description 9
• 239000000386 donor Substances 0.000 description 9
• 125000004430 oxygen atom Chemical group O* 0.000 description 9
• 230000002028 premature Effects 0.000 description 9
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 8
• 241000282414 Homo sapiens Species 0.000 description 8
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 8
• 229940049595 antibody-drug conjugate Drugs 0.000 description 8
• 239000007822 coupling agent Substances 0.000 description 8
• 231100000433 cytotoxic Toxicity 0.000 description 8
• 230000001472 cytotoxic effect Effects 0.000 description 8
• 201000010099 disease Diseases 0.000 description 8
• 238000013467 fragmentation Methods 0.000 description 8
• 238000006062 fragmentation reaction Methods 0.000 description 8
• 230000001965 increasing effect Effects 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 150000003254 radicals Chemical class 0.000 description 8
• 238000007363 ring formation reaction Methods 0.000 description 8
• 150000003335 secondary amines Chemical class 0.000 description 8
• 150000003512 tertiary amines Chemical class 0.000 description 8
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 7
• 206010025323 Lymphomas Diseases 0.000 description 7
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
• 230000001085 cytostatic effect Effects 0.000 description 7
• 125000006575 electron-withdrawing group Chemical group 0.000 description 7
• 238000003379 elimination reaction Methods 0.000 description 7
• 238000010348 incorporation Methods 0.000 description 7
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 7
• 210000004962 mammalian cell Anatomy 0.000 description 7
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 230000009257 reactivity Effects 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 6
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 6
• 230000009471 action Effects 0.000 description 6
• 150000001336 alkenes Chemical group 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 235000014633 carbohydrates Nutrition 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 230000003013 cytotoxicity Effects 0.000 description 6
• 231100000135 cytotoxicity Toxicity 0.000 description 6
• 230000008030 elimination Effects 0.000 description 6
• 229930182480 glucuronide Natural products 0.000 description 6
• 229910052736 halogen Inorganic materials 0.000 description 6
• 150000002367 halogens Chemical group 0.000 description 6
• 150000002576 ketones Chemical class 0.000 description 6
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 238000012545 processing Methods 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 239000012453 solvate Substances 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 6
• 238000011282 treatment Methods 0.000 description 6
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
• 208000017604 Hodgkin disease Diseases 0.000 description 5
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 5
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 230000010933 acylation Effects 0.000 description 5
• 238000005917 acylation reaction Methods 0.000 description 5
• 239000002168 alkylating agent Substances 0.000 description 5
• 229940100198 alkylating agent Drugs 0.000 description 5
• 230000029936 alkylation Effects 0.000 description 5
• 238000005804 alkylation reaction Methods 0.000 description 5
• 239000000611 antibody drug conjugate Substances 0.000 description 5
• 230000002238 attenuated effect Effects 0.000 description 5
• 125000001743 benzylic group Chemical group 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 230000032823 cell division Effects 0.000 description 5
• 125000004093 cyano group Chemical group *C#N 0.000 description 5
• 239000000824 cytostatic agent Substances 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 230000002708 enhancing effect Effects 0.000 description 5
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 238000010647 peptide synthesis reaction Methods 0.000 description 5
• 230000002085 persistent effect Effects 0.000 description 5
• 230000000770 proinflammatory effect Effects 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 229910052727 yttrium Inorganic materials 0.000 description 5
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 4
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 4
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 125000003545 alkoxy group Chemical group 0.000 description 4
• 150000003931 anilides Chemical class 0.000 description 4
• 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 4
• 235000013877 carbamide Nutrition 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 238000010511 deprotection reaction Methods 0.000 description 4
• 125000001033 ether group Chemical group 0.000 description 4
• 229910001385 heavy metal Inorganic materials 0.000 description 4
• 125000004474 heteroalkylene group Chemical group 0.000 description 4
• 210000005260 human cell Anatomy 0.000 description 4
• 230000003301 hydrolyzing effect Effects 0.000 description 4
• 206010020718 hyperplasia Diseases 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 208000032839 leukemia Diseases 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 230000000704 physical effect Effects 0.000 description 4
• 230000005588 protonation Effects 0.000 description 4
• 230000002269 spontaneous effect Effects 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
• 239000011593 sulfur Substances 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
• 150000003852 triazoles Chemical class 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• 102000005927 Cysteine Proteases Human genes 0.000 description 3
• 108010005843 Cysteine Proteases Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 102220595603 Major vault protein_R24C_mutation Human genes 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 3
• 206010071019 Prostatic dysplasia Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 229910052796 boron Inorganic materials 0.000 description 3
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 3
• 125000005587 carbonate group Chemical group 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 150000002170 ethers Chemical class 0.000 description 3
• 230000000763 evoking effect Effects 0.000 description 3
• 238000010353 genetic engineering Methods 0.000 description 3
• 229940097043 glucuronic acid Drugs 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 229960002989 glutamic acid Drugs 0.000 description 3
• 239000004220 glutamic acid Chemical group 0.000 description 3
• 150000005363 heterobiaryls Chemical group 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
• 235000014705 isoleucine Nutrition 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 229960003646 lysine Drugs 0.000 description 3
• 235000018977 lysine Nutrition 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 239000012038 nucleophile Substances 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000003647 oxidation Effects 0.000 description 3
• 238000007254 oxidation reaction Methods 0.000 description 3
• 238000005897 peptide coupling reaction Methods 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 150000003214 pyranose derivatives Chemical class 0.000 description 3
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 229910052710 silicon Inorganic materials 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 125000003107 substituted aryl group Chemical group 0.000 description 3
• 231100001274 therapeutic index Toxicity 0.000 description 3
• TVHNWAKCVXFPNB-HCCKASOXSA-N (4r)-4-amino-2-methyl-5-phenylpentanoic acid Chemical compound OC(=O)C(C)C[C@@H](N)CC1=CC=CC=C1 TVHNWAKCVXFPNB-HCCKASOXSA-N 0.000 description 2
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
• 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 2
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical class OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• MDKVDJZIHRFUBO-UHFFFAOYSA-N 2-amino-3-benzoyl-4-(2-benzoylphenyl)iminocyclohexa-2,5-dien-1-one Chemical compound C1=CC=C(C=C1)C(=O)C2=CC=CC=C2N=C3C=CC(=O)C(=C3C(=O)C4=CC=CC=C4)N MDKVDJZIHRFUBO-UHFFFAOYSA-N 0.000 description 2
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
• 108010083359 Antigen Receptors Proteins 0.000 description 2
• 102000006306 Antigen Receptors Human genes 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
• 125000003860 C1-C20 alkoxy group Chemical group 0.000 description 2
• 102100024940 Cathepsin K Human genes 0.000 description 2
• 102100026540 Cathepsin L2 Human genes 0.000 description 2
• 101710169274 Cathepsin L2 Proteins 0.000 description 2
• 102000005600 Cathepsins Human genes 0.000 description 2
• 108010084457 Cathepsins Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 102000053187 Glucuronidase Human genes 0.000 description 2
• 108010060309 Glucuronidase Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000004157 Hydrolases Human genes 0.000 description 2
• 108090000604 Hydrolases Proteins 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
• 102000005741 Metalloproteases Human genes 0.000 description 2
• 108010006035 Metalloproteases Proteins 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
• 229910018828 PO3H2 Inorganic materials 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 102000012479 Serine Proteases Human genes 0.000 description 2
• 108010022999 Serine Proteases Proteins 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 229920002253 Tannate Polymers 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 102000004243 Tubulin Human genes 0.000 description 2
• 108090000704 Tubulin Proteins 0.000 description 2
• FPPZQGWDBRTKFZ-UHFFFAOYSA-N [N].O=C1CCC(=O)N1 Chemical compound [N].O=C1CCC(=O)N1 FPPZQGWDBRTKFZ-UHFFFAOYSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 150000001335 aliphatic alkanes Chemical class 0.000 description 2
• 125000002877 alkyl aryl group Chemical group 0.000 description 2
• 150000005215 alkyl ethers Chemical class 0.000 description 2
• 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
• 235000008206 alpha-amino acids Nutrition 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 229940072107 ascorbate Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 229960005261 aspartic acid Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 229940077388 benzenesulfonate Drugs 0.000 description 2
• 150000001576 beta-amino acids Chemical class 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 238000010504 bond cleavage reaction Methods 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical class NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000006227 byproduct Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
• 125000002843 carboxylic acid group Chemical group 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 229940001468 citrate Drugs 0.000 description 2
• 210000003690 classically activated macrophage Anatomy 0.000 description 2
• 238000010668 complexation reaction Methods 0.000 description 2
• 238000006482 condensation reaction Methods 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 239000012039 electrophile Substances 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 201000003444 follicular lymphoma Diseases 0.000 description 2
• 229940050411 fumarate Drugs 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 229940050410 gluconate Drugs 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 229940097042 glucuronate Drugs 0.000 description 2
• 229940049906 glutamate Drugs 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 229930182470 glycoside Natural products 0.000 description 2
• 150000002338 glycosides Chemical class 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• 239000008241 heterogeneous mixture Substances 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
• CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 229940076144 interleukin-10 Drugs 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 2
• 208000003747 lymphoid leukemia Diseases 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 230000002132 lysosomal effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 2
• 229940049964 oleate Drugs 0.000 description 2
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 229960005190 phenylalanine Drugs 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 150000003141 primary amines Chemical class 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
• 229960001860 salicylate Drugs 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 125000005017 substituted alkenyl group Chemical group 0.000 description 2
• 125000004426 substituted alkynyl group Chemical group 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 229940095064 tartrate Drugs 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 229960004441 tyrosine Drugs 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 150000003672 ureas Chemical class 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• BSPMWFRGZQDRIU-UHFFFAOYSA-N (2-amino-1h-imidazol-5-yl)methanol Chemical class NC1=NC(CO)=CN1 BSPMWFRGZQDRIU-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• FMBGOORJEKQQLG-LXOXETEGSA-N (2s)-6-amino-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl Chemical group C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 FMBGOORJEKQQLG-LXOXETEGSA-N 0.000 description 1
• PCLMSUBZTGCHQT-WCBMZHEXSA-N (2s,4r)-4-amino-5-(4-hydroxyphenyl)-2-methylpentanoic acid Chemical compound OC(=O)[C@@H](C)C[C@@H](N)CC1=CC=C(O)C=C1 PCLMSUBZTGCHQT-WCBMZHEXSA-N 0.000 description 1
• 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
• 125000006736 (C6-C20) aryl group Chemical group 0.000 description 1
• JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
• XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical group N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
• 125000006039 1-hexenyl group Chemical group 0.000 description 1
• 125000006023 1-pentenyl group Chemical group 0.000 description 1
• HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
• 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 1
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
• GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
• 125000006041 3-hexenyl group Chemical group 0.000 description 1
• LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• WJQDJDVDXAAXSB-UHFFFAOYSA-N 5-sulfanylidenepyrrolidin-2-one Chemical compound O=C1CCC(=S)N1 WJQDJDVDXAAXSB-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 108091005508 Acid proteases Proteins 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
• 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
• 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• SUITWKKZPSZGOO-JKSUJKDBSA-N C(CN([C@@H](C[C@H](C1=NC(=CS1)C(=O)OCC)O)C(C)C)C(=O)OC(C)(C)C)C Chemical compound C(CN([C@@H](C[C@H](C1=NC(=CS1)C(=O)OCC)O)C(C)C)C(=O)OC(C)(C)C)C SUITWKKZPSZGOO-JKSUJKDBSA-N 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 125000004411 C5-C6 heterocyclyl group Chemical group 0.000 description 1
• 125000006519 CCH3 Chemical group 0.000 description 1
• 125000006414 CCl Chemical group ClC* 0.000 description 1
• 102100025221 CD70 antigen Human genes 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 108010059081 Cathepsin A Proteins 0.000 description 1
• 102000005572 Cathepsin A Human genes 0.000 description 1
• 108090000712 Cathepsin B Proteins 0.000 description 1
• 102000004225 Cathepsin B Human genes 0.000 description 1
• 102000003902 Cathepsin C Human genes 0.000 description 1
• 108090000267 Cathepsin C Proteins 0.000 description 1
• 102000003908 Cathepsin D Human genes 0.000 description 1
• 108090000258 Cathepsin D Proteins 0.000 description 1
• 102000004178 Cathepsin E Human genes 0.000 description 1
• 108090000611 Cathepsin E Proteins 0.000 description 1
• 108090000610 Cathepsin F Proteins 0.000 description 1
• 102000004176 Cathepsin F Human genes 0.000 description 1
• 108090000617 Cathepsin G Proteins 0.000 description 1
• 102000004173 Cathepsin G Human genes 0.000 description 1
• 108090000619 Cathepsin H Proteins 0.000 description 1
• 102000004175 Cathepsin H Human genes 0.000 description 1
• 108090000625 Cathepsin K Proteins 0.000 description 1
• 101710177066 Cathepsin O Proteins 0.000 description 1
• 108090000613 Cathepsin S Proteins 0.000 description 1
• 102100035654 Cathepsin S Human genes 0.000 description 1
• 108010061112 Cathepsin W Proteins 0.000 description 1
• 102000011933 Cathepsin W Human genes 0.000 description 1
• 108010061117 Cathepsin Z Proteins 0.000 description 1
• 102000011937 Cathepsin Z Human genes 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008263 Cervical dysplasia Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
• 201000003791 MALT lymphoma Diseases 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
• BPSLZWSRHTULGU-UHFFFAOYSA-N Methylpipecolic acid Chemical compound CN1CCCCC1C(O)=O BPSLZWSRHTULGU-UHFFFAOYSA-N 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• ROGDNKUDRQBJBX-UONOGXRCSA-N N=1C(C(=O)OCC)=CSC=1[C@@H](C[C@H](N(C)C(=O)OC(C)(C)C)C(C)C)O Chemical compound N=1C(C(=O)OCC)=CSC=1[C@@H](C[C@H](N(C)C(=O)OC(C)(C)C)C(C)C)O ROGDNKUDRQBJBX-UONOGXRCSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
• 229910003849 O-Si Inorganic materials 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 229910003872 O—Si Inorganic materials 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102000035100 Threonine proteases Human genes 0.000 description 1
• 108091005501 Threonine proteases Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• AKDLZRSCZBAIQF-UHFFFAOYSA-N [N].C1(C=CC(N1)=O)=O Chemical compound [N].C1(C=CC(N1)=O)=O AKDLZRSCZBAIQF-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 229960003767 alanine Drugs 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 150000001345 alkine derivatives Chemical group 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 125000005336 allyloxy group Chemical group 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 150000001491 aromatic compounds Chemical class 0.000 description 1
• 230000037007 arousal Effects 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 238000005815 base catalysis Methods 0.000 description 1
• 238000011021 bench scale process Methods 0.000 description 1
• 125000005605 benzo group Chemical group 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
• 150000005347 biaryls Chemical group 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 230000000981 bystander Effects 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 150000001793 charged compounds Chemical class 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 150000001924 cycloalkanes Chemical class 0.000 description 1
• 150000001925 cycloalkenes Chemical class 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 229960002433 cysteine Drugs 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000002559 cytogenic effect Effects 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 239000012351 deprotecting agent Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• NALBLJLOBICXRH-UHFFFAOYSA-N dinitrogen monohydride Chemical group N=[N] NALBLJLOBICXRH-UHFFFAOYSA-N 0.000 description 1
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
• 201000006828 endometrial hyperplasia Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 239000004210 ether based solvent Substances 0.000 description 1
• ANPYLYUCGAFKNQ-UHFFFAOYSA-N ethoxymethoxymethoxyethane Chemical class CCOCOCOCC ANPYLYUCGAFKNQ-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 150000002243 furanoses Chemical class 0.000 description 1
• 150000002271 geminal diols Chemical class 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960002743 glutamine Drugs 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 150000002373 hemiacetals Chemical group 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 150000002391 heterocyclic compounds Chemical class 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
• 235000014304 histidine Nutrition 0.000 description 1
• 229960002885 histidine Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000036732 histological change Effects 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 239000000852 hydrogen donor Substances 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 235000005772 leucine Nutrition 0.000 description 1
• 229960003136 leucine Drugs 0.000 description 1
• WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 239000012931 lyophilized formulation Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 201000000638 mature B-cell neoplasm Diseases 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 235000006109 methionine Nutrition 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960004452 methionine Drugs 0.000 description 1
• NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical compound [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 208000010915 neoplasm of mature B-cells Diseases 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• HKKDKUMUWRTAIA-UHFFFAOYSA-N nitridooxidocarbon(.) Chemical compound [O]C#N HKKDKUMUWRTAIA-UHFFFAOYSA-N 0.000 description 1
• 150000002829 nitrogen Chemical group 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 125000000962 organic group Chemical group 0.000 description 1
• 125000002524 organometallic group Chemical group 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 125000005561 phenanthryl group Chemical group 0.000 description 1
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000003334 potential effect Effects 0.000 description 1
• 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000000651 prodrug Chemical group 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 229960002429 proline Drugs 0.000 description 1
• 235000013930 proline Nutrition 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000005956 quaternization reaction Methods 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 230000002000 scavenging effect Effects 0.000 description 1
• 229960001153 serine Drugs 0.000 description 1
• 235000004400 serine Nutrition 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• DVFXLNFDWATPMW-IWOKLKJTSA-N tert-butyldiphenylsilyl Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DVFXLNFDWATPMW-IWOKLKJTSA-N 0.000 description 1
• 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 235000008521 threonine Nutrition 0.000 description 1
• 229960002898 threonine Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960004799 tryptophan Drugs 0.000 description 1
• 238000010518 undesired secondary reaction Methods 0.000 description 1
• 229940070710 valerate Drugs 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 235000014393 valine Nutrition 0.000 description 1
• 229960004295 valine Drugs 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1